Total Visits

Views
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group16

Total Visits Per Month

May 2019June 2019July 2019August 2019September 2019October 2019November 2019
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group0050622

Top country views

Views
Poland12
France3

Top cities views

Views
Warsaw12